Loss of Heterozygosity of FCY2 Leading to the Development of Flucytosine Resistance in Candida tropicalis
暂无分享,去创建一个
[1] W. Ko,et al. Species distribution and antifungal susceptibility of blood Candida isolates at a tertiary hospital in southern Taiwan, 1999–2006 , 2011, Mycoses.
[2] M. Falagas,et al. Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review. , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[3] S. Katiyar,et al. Mutational Analysis of Flucytosine Resistance in Candida glabrata , 2010, Antimicrobial Agents and Chemotherapy.
[4] A. Hasegawa,et al. Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity. , 2010, The Journal of antimicrobial chemotherapy.
[5] B. Dujon,et al. Population Polymorphism of Nuclear Mitochondrial DNA Insertions Reveals Widespread Diploidy Associated with Loss of Heterozygosity in Debaryomyces hansenii , 2010, Eukaryotic Cell.
[6] A. Wang,et al. The distribution of species and susceptibility of amphotericin B and fluconazole of yeast pathogens isolated from sterile sites in Taiwan. , 2010, Medical mycology.
[7] Yu-Hsin Lin,et al. The molecular epidemiology of serial Candida tropicalis isolates from ICU patients as revealed by multilocus sequence typing and pulsed-field gel electrophoresis. , 2009, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[8] B. Da Silva,et al. Nonsense and Missense Mutations in FCY2 and FCY1 Genes Are Responsible for Flucytosine Resistance and Flucytosine-Fluconazole Cross-Resistance in Clinical Isolates of Candida lusitaniae , 2009, Antimicrobial Agents and Chemotherapy.
[9] P. D. Rogers,et al. Mutations in the multi‐drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole‐resistant Candida albicans strains , 2008, Molecular microbiology.
[10] D. Gottschling,et al. A Genetic Screen for Increased Loss of Heterozygosity in Saccharomyces cerevisiae , 2008, Genetics.
[11] Yun-Liang Yang,et al. Susceptibilities to amphotericin B and fluconazole of Candida species in Taiwan Surveillance of Antimicrobial Resistance of Yeasts 2006. , 2008, Diagnostic microbiology and infectious disease.
[12] D. Shaw,et al. Molecular phylogenetic analysis of Candida tropicalis isolates by multi-locus sequence typing. , 2008, Fungal genetics and biology : FG & B.
[13] F. Dromer,et al. Clonal Population of Flucytosine-Resistant Candida tropicalis from Blood Cultures, Paris, France , 2008, Emerging infectious diseases.
[14] Clinical,et al. Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard , 2008 .
[15] H. Lo,et al. Multilocus sequence typing of Candida tropicalis shows clonal cluster enriched in isolates with resistance or trailing growth of fluconazole. , 2007, Diagnostic microbiology and infectious disease.
[16] P. Tambyah,et al. Predominance of Candida tropicalis bloodstream infections in a Singapore teaching hospital. , 2007, Medical mycology.
[17] N. Jain,et al. Epidemiology of Candidemia in a Tertiary Care Centre of North India: 5-Year Study , 2007, Infection.
[18] Yun-Liang Yang,et al. Association between fluconazole susceptibility and genetic relatedness among Candida tropicalis isolates in Taiwan. , 2007, Journal of medical microbiology.
[19] M. Pfaller,et al. Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem , 2007, Clinical Microbiology Reviews.
[20] Hsi-Tsung Cheng,et al. Solution structure of a novel D-naphthylalanine substituted peptide with potential antibacterial and antifungal activities. , 2007, Biopolymers.
[21] D. Warnock. Trends in the epidemiology of invasive fungal infections. , 2007, Nihon Ishinkin Gakkai zasshi = Japanese journal of medical mycology.
[22] J. Villard,et al. Molecular Mechanism of Flucytosine Resistance in Candida lusitaniae: Contribution of the FCY2, FCY1, and FUR1 Genes to 5-Fluorouracil and Fluconazole Cross-Resistance , 2006, Antimicrobial Agents and Chemotherapy.
[23] J. Berman,et al. A Mutation in Tac1p, a Transcription Factor Regulating CDR1 and CDR2, Is Coupled With Loss of Heterozygosity at Chromosome 5 to Mediate Antifungal Resistance in Candida albicans , 2006, Genetics.
[24] J. Villard,et al. Inactivation of the FCY2 Gene Encoding Purine-Cytosine Permease Promotes Cross-Resistance to Flucytosine and Fluconazole in Candida lusitaniae , 2005, Antimicrobial Agents and Chemotherapy.
[25] Yun-Liang Yang,et al. Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2002. , 2005, Diagnostic microbiology and infectious disease.
[26] P. T. Magee,et al. Demonstration of Loss of Heterozygosity by Single-Nucleotide Polymorphism Microarray Analysis and Alterations in Strain Morphology in Candida albicans Strains during Infection , 2005, Eukaryotic Cell.
[27] D. Sanglard,et al. TAC1, Transcriptional Activator of CDR Genes, Is a New Transcription Factor Involved in the Regulation of Candida albicans ABC Transporters CDR1 and CDR2 , 2004, Eukaryotic Cell.
[28] L. Tabernero,et al. Molecular Mechanisms of Primary Resistance to Flucytosine in Candida albicans , 2004, Antimicrobial Agents and Chemotherapy.
[29] R. Kolter,et al. The SAT1 flipper, an optimized tool for gene disruption in Candida albicans. , 2004, Gene.
[30] D. Soll,et al. Clade-Specific Flucytosine Resistance Is Due to a Single Nucleotide Change in the FUR1 Gene of Candida albicans , 2004, Antimicrobial Agents and Chemotherapy.
[31] Yun-Liang Yang,et al. Susceptibilities of Candida Species to Amphotericin B and Fluconazole: The Emergence of Fluconazole Resistance in Candida tropicalis , 2004, Infection Control & Hospital Epidemiology.
[32] Yun-Liang Yang,et al. Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999. , 2003, Diagnostic microbiology and infectious disease.
[33] Yun-Liang Yang,et al. Mechanisms of antifungal agent resistance. , 2001, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.
[34] H. Guchelaar,et al. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. , 2000, The Journal of antimicrobial chemotherapy.
[35] D. Sanglard,et al. Experimental Induction of Fluconazole Resistance in Candida tropicalis ATCC 750 , 2000, Antimicrobial Agents and Chemotherapy.
[36] L. Cowen,et al. Evolution of Drug Resistance in Experimental Populations of Candida albicans , 2000, Journal of bacteriology.
[37] Ronald N. Jones,et al. Bloodstream Infections Due to Candida Species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998 , 2000, Antimicrobial Agents and Chemotherapy.
[38] D. Kelly,et al. Multiple Molecular Mechanisms Contribute to a Stepwise Development of Fluconazole Resistance in Clinical Candida albicans Strains , 1998, Antimicrobial Agents and Chemotherapy.
[39] T. C. White,et al. Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance , 1998, Clinical Microbiology Reviews.
[40] T. C. White,et al. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans , 1997, Antimicrobial agents and chemotherapy.
[41] S. Filler,et al. Reversible fluconazole resistance in Candida albicans: a potential in vitro model , 1997, Antimicrobial agents and chemotherapy.
[42] F. Sherman. Getting started with yeast. , 1991, Methods in enzymology.
[43] A. Polak,et al. Mechanisms of action of 5-fluorocytosine , 1983, Antimicrobial Agents and Chemotherapy.
[44] J. E. Bennett,et al. Mode of action of 5-fluorocytosine. , 1978, Biochemical pharmacology.
[45] A. Polak,et al. Mode of action of 5-fluorocytosine and mechanisms of resistance. , 1975, Chemotherapy.